Publications by authors named "Alan Czeszynski"
Introduction: Retinal imaging is a non-invasive tool to study both retinal vasculature and neurodegeneration. In this exploratory retinal curcumin-fluorescence imaging (RFI) study, we sought to determine whether retinal vascular features combined with retinal amyloid burden correlate with the neurocognitive status.
Methods: We used quantitative RFI in a cohort of patients with cognitive impairment to automatically compute retinal amyloid burden.
Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline.
Alzheimers Dement (Amst)
September 2020
Article Synopsis
- A study investigated retinal amyloid beta levels in 34 patients with cognitive decline using a special imaging technique, finding a link between retinal amyloid and brain changes.
- Results showed that higher retinal amyloid levels were associated with lower hippocampal volume and poorer cognitive scores, particularly in individuals with mild cognitive impairment and Alzheimer's disease.
- The authors concluded that this retinal imaging method could help predict brain health, and future research should explore its use as an early biomarker for Alzheimer's disease.
Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment.
Am J Alzheimers Dis Other Demen
December 2020
Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS).
Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.
Purpose: To report the incidence and features of retinal microvascular abnormalities (MVAs) occurring secondary to stereotactic radiotherapy (SRT) in a randomised double-masked sham-controlled clinical trial at 21 European sites.
Methods: Two hundred and thirty participants with neovascular age-related macular degeneration (AMD) treated with at least three intravitreal antivascular endothelial growth factor (anti-VEGF) injections prior to enrolment, and demonstrating a continuing need for re-treatment.
Interventions: 16 Gy, 24 Gy or sham SRT.